Table 6.
Risk of cardiovascular diseases in the two drug groups after matching between 2016 and 2018 (with cardiovascular disease history)
| Classification | Febuxostat (5466 patients) | Allopurinol (5466 patients) | HR (95% CI) |
||||
|---|---|---|---|---|---|---|---|
| Number of patients (n) |
Person–years | Incidence rate (1000 person –years) | Number of patients (n) | Person–years | Incidence rate (1000 person –years) | ||
| Primary outcome variable* | |||||||
| Cardiovascular disease | 2747 | 2566.6 | 1070.3 | 2769 | 2883.0 | 960.4 | 1.03 (0.98–1.09) |
| Secondary outcome variable | |||||||
| Myocardial infarction | 164 | 4,683.2 | 35.0 | 184 | 5,274.6 | 34.9 | 0.94 (0.76–1.16) |
| Ischemic heart disease | 641 | 4,274.7 | 150.0 | 663 | 4,853.4 | 136.6 | 1.02 (0.91–1.13) |
| Stroke | 1,016 | 3,977.9 | 255.4 | 1053 | 4,465.3 | 235.8 | 0.99 (0.91–1.08) |
| Transient ischemic attack | 192 | 4,659.6 | 41.2 | 193 | 5,259.0 | 36.7 | 1.04 (0.85–1.27) |
| Heart failure | 1,115 | 3,944.0 | 282.7 | 1176 | 4,389.1 | 267.9 | 0.99 (0.91–1.07) |
| Coronary revascularization (treatment) | 51 | 4,775.3 | 10.7 | 50 | 5,399.2 | 9.3 | 1.09 (0.71–1.67) |
| All-cause death | 4 | 2,566.6 | 1.6 | 4 | 2,883.0 | 1.4 | 1.16 (0.29–4.65) |
*All-cause death: includes 4 patients in each of the two groups
Coronary revascularization is a treatment code that has secondary outcome variables and overlapping values